FDA Approves Ionis Pharmaceuticals' Zanvastro as First Treatment for Rare Alexander Disease

Ionis Pharmaceuticals has received FDA approval for Zanvastro, marking the first disease-modifying treatment for Alexander disease. Clinical trials demonstrated that patients receiving the drug maintained their walking speed, while untreated control patients suffered a 33% decline in motor function. Trial data indicates the treatment was generally safe, with severe adverse events occurring more frequently in the untreated cohort than in treated patients. Early indicators suggest that administering the therapy to young children may actively improve their motor function rather than simply halting the disease's progression.